Active Pharma Ingredient Market Scope
The Active Pharmaceutical Ingredient (API) is the chief therapeutic entity in a drug product and it is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place.
The market study is being classified by Type (Innovative Active Pharmaceutical Ingredients and Generic Active Pharmaceutical Ingredients), by Application (Oncology, Cardiovascular Disease, Diabetes, Central Nervous System and Neurological Disorders, Endocrinology, Pain Management and Others) and major geographies with country level break-up. According to AMA, the Global Active Pharma Ingredient market is expected to see growth rate of 5.93% and may see market size of USD248.3 Billion by 2025.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.The Players having a strong hold in the market are Teva Pharmaceutical Industries Ltd, Novartis International AG, Pfizer Inc. , and Johnson & Johnson. Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global Active Pharma Ingredient market throughout the predicted period.
Teva Pharmaceutical Industries Ltd (Israel), Novartis International AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson (United States), Mylan N.V. (United States), BASF SE (Germany), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), AbbVie Inc. (United States),, AstraZeneca plc (United Kingdom), North China Pharmaceutical Group (China), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany) and Cambrex (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Aurobindo Pharma (India), Sun Pharmaceutical Industries (India), Boehringer Ingelheim GmbH (Germany), Koninklijke DSM N.V. (Netherlands), Zhejiang Medicine Co., Ltd. (China), Biocon Limited (India), Johnson Matthey (United Kingdom), Zhejiang Hisun Pharmaceutical Co. Ltd (China), Shandong Xinhua Pharmaceutical (China), Lonza Group (Switzerland), Huahai Pharmaceutical (China) and Haerbin Pharmaceutical Group (China).
AdvanceMarketAnalytics has segmented the market of Global Active Pharma Ingredient market by Type, Application and Region.
On the basis of geography, the market of Active Pharma Ingredient has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.
Market Leaders and their expansionary development strategies
On 31st January 2020, Sandoz has announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly-owned subsidiary of Aspen Pharmacare Holdings Limited. Sandoz has acquired all of the shares in Aspen Japan K.K. and associated assets held by AGI.
On 14th September 2018, Lonza Pharma & Biotech has announced the launch of its pharmaceutical early-intermediates supply initiative. The initiative leverages chemical production facilities at the company’s Visp (CH) site to address increasing global early-intermediates supply security and quality concerns. Lonza now offers its customers an integrated supply chain from non-GMP early intermediates to cGMP advanced intermediates and APIs.
- Increasing Adoption of Artificial Intelligence-Based Tools for Drug Discovery
- Rising Incidence of Chronic Diseases like Cancer
- Increasing Importance of Generics Medicines in Developing Economies Upsirging Adoption of Organ-On-Chip Models in Drug Development
- Growing Focus on Precision Medicine
- Technological Advancements and Development in API Manufacturing
- Rising Investments in Real-World Evidence By Pharmaceutical Companies
- Highly Potent Active Pharmaceutical Ingredients
- Unfavorable Drug Price Control Policies Across Various Countries
- Increasing Penetration of Counterfeit Drugs
- Product Differentiation - A Major Concern for API Manufacturers
- High Manufacturing Costs
Key Target AudienceActive Pharma Ingredient Manufacturers, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Other
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase